Jim Czirr is the executive chairman and a founding shareholder of Galectin Therapeutics, Inc., a company developing novel treatments for two diseases: liver cirrhosis and cancer. He is the founder and general partner of 10X Fund, a venture capital fund that is a large investor in Galectin Therapeutics. After co-founding the company in 2000, Mr. Czirr left the company's employment in 2003 to do corporate...
Steve Hamner has been involved in real estate, accounting, and finance for more than 20 years and is a founder of Medical Properties Trust, where he currently serves as executive vice president and chief financial officer. Previously, Mr. Hamner was the managing director of Transaction Analysis, LLC, a company that provided interim and project-oriented accounting and consulting services to commercial...
George Tidmarsh, PhD, has 22 years of experience in biotechnology, which include the successful clinical development of three FDA-approved drugs. Up until his appointment to La Jolla Pharmaceuticals, he served as the chief executive officer of Solana Therapeutics, Inc. Previously, Dr. Tidmarsh served as the chief executive officer of Horizon Pharma, Inc., (NASDAQ: HZNP), a company he founded in...
As regulations pressure medical facilities to do some major cost-cutting, this company is positioned to prosper, says Benjamin Shepherd of Personal Finance.
The shares of this company have been hit hard by selling pressure unrelated to the strength or weakness of the stock itself, which may mean a nice bargain, writes Taesik Yoon of Forbes Investor.
Buy and hold investing is unlikely to work in a major crash, so Harry Dent shares a few sectors he would want to carefully buy into if the market topples.